Baird lowered the firm’s price target on iRhythm to $110 from $120 and keeps an Outperform rating on the shares. The firm said they delivered another beat/raise on all levels, with comp-adj accelerating growth. However, the new FDA 483-observation was a bit of a surprise, that we suspect will raise questions to recently delayed Warning Letter resolution/ZioMCT submission timelines.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Irhythm Technologies CFO Transition and Financial Arrangements
- iRhythm Technologies Announces Second Quarter 2024 Financial Results
- iRhythm Technologies Announces Chief Financial Officer Transition
- iRhythm Technologies to Report Second Quarter 2024 Financial Results on August 1, 2024
- iRhythm price target lowered to $134 from $145 at Truist